<DOC>
	<DOC>NCT00778882</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of administration of autologous hematopoietic stem cells transduced with MT-gp91 retroviral vector for patients with X-linked chronic granulomatous disease.</brief_summary>
	<brief_title>Gene Therapy for Chronic Granulomatous Disease in Korea</brief_title>
	<detailed_description />
	<mesh_term>Granulomatous Disease, Chronic</mesh_term>
	<mesh_term>Granuloma</mesh_term>
	<criteria>gp91 defective male patients with chronic granulomatous disease: confirmed by DHR Weigh greater than or equal to 15 kg History of severe infections: more than 2 times Performance status: ECOG 02 Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. Heart: a shortening fraction &gt; 28%; QTc interval &lt; 0.44 Liver: total bilirubin &lt; 2 × upper limit of normal; ALT &lt; 3 × upper limit of normal; AST &lt; 3 x upper limit of normal Kidney: creatine &lt; 2 x normal Blood: WBC &gt; 2,500/uL; platelet &gt; 100,000/uL; hematocrit &gt; 26% Written informed consent obtained from patient (or guardian if patients age &lt; 19) Presence of a HLAmatched sibling for stem cell donation Evidence or history of malignant tumor Presence of a severe infection Presence of an active tuberculosis Uncorrectable electrolyte, Ca, P Unable to comply with the protocol or to cooperate fully with the Investigator or site personnel</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Chronic Granulomatous Disease</keyword>
	<keyword>Retroviral Vector</keyword>
	<keyword>Gene Therapy</keyword>
</DOC>